insights_auto
Miks on IPSEY langenud? 2,60%?
Uurige põhjalikumaltchevron_right
IPSEY:OTCMKTS
Ipsen ADR Rep 1/4 Ord Shs
40,89 $
arrow_downward
−2,60%(−1,09) 1 p
28. sept, 16:00:00 GMT −4 · USD
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse IPSEY põhistatistika genereerimine…
Ava
40,31 $
Kõrge
40,89 $
Madal
40,31 $
Turu kapit.
11,97 mld
Keskm. maht
513,00
Maht
515,00
52 näd kõrgeim
51,10 $
52 näd madalaim
32,68 $
Beeta
0,41
Käibivad aktsiad
335,26 mln
Töötajate arv
6 tuh
Ava
40,31 $
Kõrge
40,89 $
Madal
40,31 $
Turu kapit.
11,97 mld
Keskm. maht
513,00
Maht
515,00
52 näd kõrgeim
51,10 $
52 näd madalaim
32,68 $
Beeta
0,41
Käibivad aktsiad
335,26 mln
Töötajate arv
6 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
Yahoo Finance UK
·
12 tunni eest
GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
Stock Titan
·
13 tunni eest
About €147 per share was the average price in Ipsen's two-day buyback.
Profiil
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
Teave üksuse Ipsen ADR Rep 1/4 Ord Shs kohta